Journal for Clinical Studies 3.5

No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.

Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.

The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.

Our global team of cancer experts are on hand to provide support and advice to both patients and fellow RGCC clinicians. It’s very simple:

1. Head to the Cancer A-Z app and navigate to the “Consultations” area.
2. You will be asked to complete a short online questionnaire to give us more information about your current concerns or requirements.
3. You will browse a shortlist of RGCC Network clinicians who can best help your needs.
4. Select your chosen consultant and then select your preferred consultation date and time using our interactive calendar.
5. You will receive a notification in our secure messaging area to confirm your appointment. If your consultant requires additional information before your meeting, they will contact you via the secure messaging area.

Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.